Astellas announced that a patient participating in the phase 1/2 ASPIRO trial has died. The trial is evaluating AT132 in patients with X-linked Myotubular Myopathy…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.